Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583543 | 0.94 | EPHX1 (0.66) | EPHX1POLBRAB9ANPC1HPGD | |
| SCHEMBL12196182 | 0.85 | EPHX1 (1.00) | EPHX1POLBRAB9ANPC1HPGD | |
| SCHEMBL584201 | 0.80 | EPHX1 (0.71) | EPHX1POLBRAB9ANPC1HPGD | |
| SCHEMBL6436349 | 0.79 | EPHX1 (1.00) | EPHX1RAB9ANPC1HPGDL3MBTL1 | |
| SCHEMBL34468086 | 0.79 | RAB9A (1.00) | EPHX1POLBRAB9ANPC1L3MBTL1 | |
| SCHEMBL12852553 | 0.78 | EPHX1 (0.67) | EPHX1POLBRAB9ANPC1HPGD | |
| SCHEMBL2752603 | 0.77 | EPHX1 (0.97) | EPHX1RAB9ANPC1HPGDL3MBTL1 | |
| SCHEMBL583544 | 0.77 | POLB (0.57) | EPHX1POLBRAB9ANPC1PTPN1 | |
| SCHEMBL4865028 | 0.77 | PTPN1 (0.68) | PTPN1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL15270999 | 0.77 | SIGMAR1 (0.74) | POLBRAB9ANPC1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417120-B1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-10-26 | — | — | EP | disclosed |
| CN-102388032-B | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INT | 2015-01-14 | — | — | CN | disclosed |
| US-RE45323-E1 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| CN-102388032-A | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INT | 2012-03-21 | — | — | CN | disclosed |
| EP-2417120-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115836-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | EPHX1 1463/4885POLB 4121/4885RAB9A 2096/4885 |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | CCR3, CCR1, CCR4 | EPHX1 1251/4885POLB 3997/4885RAB9A 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.